月期刊平台服务过的文章录用时间为1-3个月，依据20年经验，经月期刊专家预审通过后的文章，投稿通过率100%以上！
血管病是西方国家最常见的死因，其发病率在发展中国家呈上升趋势。因此，大量的研究旨在建立有效的治疗急性血管事件。长期治疗也受到了相当大的关注（例如症状缓解）。此外，有效的预防，无论是一级还是二级，都得到了几个具有里程碑意义的试验结果的支持。血管疾病是一个复杂的领域，有初级保健医师和护士从业人员以及涉及的几个专业。后者包括心脏病学、血管和心胸外科、普通医学、放射学、临床药理学和神经学（中风单元）。目前的血管药理学将发表评论，以更新所有与血管疾病治疗有关的。例如，对最近发表的试验或新药的评论将包括在内。除了临床相关主题外，我们还将考虑“基于研究”的评论，以处理未来的发展和潜在的药物目标。因此，当前血管药理学的另一个功能是弥合临床实践和正在进行的研究之间的差距。本杂志的通讯部分也将鼓励辩论。
http://benthamscience.com/journal/authors-guidelines.php?journalID=cvp#top
Vascular disease is the commonest cause of death in Westernized countries and its incidence is on the increase in developing countries. It follows that considerable research is directed at establishing effective treatment for acute vascular events. Long-term treatment has also received considerable attention (e.g. for symptomatic relief). Furthermore, effective prevention, whether primary or secondary, is backed by the findings of several landmark trials. Vascular disease is a complex field with primary care physicians and nurse practitioners as well as several specialties involved. The latter include cardiology, vascular and cardio thoracic surgery, general medicine, radiology, clinical pharmacology and neurology (stroke units). Current Vascular Pharmacology will publish reviews to update all those concerned with the treatment of vascular disease. For example, reviews commenting on recently published trials or new drugs will be included. In addition to clinically relevant topics we will consider 'research-based' reviews dealing with future developments and potential drug targets. Therefore, another function of Current Vascular Pharmacology is to bridge the gap between clinical practice and ongoing research. Debates will also be encouraged in the correspondence section of this journal.
